Compounding pharmacy sues Lilly, Novo over GLP-1 drug competition

Arizona-based Strive Compounding Pharmacy has sued Eli Lilly (LLY) and Novo Nordisk (NVO) in a Texas federal court alleging that the drug giants coordinated to stifle competition by hindering access to compounded versions of their blockbuster GLP-1